Skip to content

A Prospective Cohort Study on the Association Between Serum AQP4-IgG Levels and the Risk of Disease Relapse in Neuromyelitis Optica Spectrum Disorders (NMOSD) During the Peri-pregnancy Period

A Prospective Cohort Study on the Association Between Serum AQP4-IgG Levels and the Risk of Disease Relapse in Neuromyelitis Optica Spectrum Disorders (NMOSD) During the Peri-pregnancy Period

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122506
Enrollment
Unknown
Registered
2026-04-14
Start date
2026-02-05
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Interventions

Observational group:None

Sponsors

The Third Affiliated Hospital Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.Females aged 18–45 years inclusive. 2.Diagnosis of AQP4-IgG-positive NMOSD according to the 2015 Wingerchuk International Consensus Diagnostic Criteria. 3.Has a confirmed intention to become pregnant within the subsequent 12 months. 4.EDSS score <= 3.0 at enrollment, with mild disability, independent ambulation, and full capacity for study follow-up. 5.No NMOSD relapse within 12 months before enrollment, with disease in stable condition. 6.On long-term maintenance immunosuppressive therapy with azathioprine at enrollment. 7.Able to comprehend the study protocol, provide voluntary written informed consent, and comply with the long-term follow-up schedule from pre-pregnancy through 1 year postpartum.

Exclusion criteria

Exclusion criteria: 1.Complicated with systemic autoimmune diseases (such as systemic lupus erythematosus, Sjögren's syndrome, etc.); 2.Complicated with severe dysfunction of major organs such as heart, liver and kidney. 3.Presence of severe psychiatric illness or cognitive dysfunction, resulting in inability to cooperate with follow-up. 4.Documented history of absolute contraindications to pregnancy, such as severe preeclampsia or recurrent miscarriage caused by uterine malformation. 5.Currently participating in any other interventional clinical trial. 6.Voluntary withdrawal and revocation of informed consent during the study period.

Design outcomes

Primary

MeasureTime frame
Relapse or no relapse during peri-pregnancy in NMOSD patients;

Secondary

MeasureTime frame
Maternal outcomes: Gestational hypertension, preeclampsia/eclampsia, gestational diabetes, thyroid dysfunction during pregnancy, mode of delivery (natural delivery/cesarean section), major obstetric complications (such as postpartum hemorrhage, puerperium infection, etc.);Fetal/neonatal outcomes: miscarriage (=20 weeks of gestation), gestational age at birth, preterm birth (<37 weeks of gestation), birth weight, Apgar score, congenital malformations, admission status and duration to the neonatal intensive care unit (NICU).;

Countries

China

Contacts

Public ContactXiao Li

The Third Affiliated Hospital Sun Yat-sen University

13430294770@163.com+86 20 85252336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026